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Abstract
Background: The CDC’s Family History Public Health Initiative encourages adoption and increase awareness of
family health history. To meet these goals and develop a personalized medicine implementation science research
agenda, the Genomedical Connection is using an implementation research (T3 research) framework to develop and
integrate a self-administered computerized family history system with built-in decision support into 2 primary care
clinics in North Carolina.
Methods/Design: The family health history system collects a three generation family history on 48 conditions and
provides decision support (pedigree and tabular family history, provider recommendation report and patient
summary report) for 4 pilot conditions: breast cancer, ovarian cancer, colon cancer, and thrombosis. All adult
English-speaking, non-adopted, patients scheduled for well-visits are invited to complete the family health system
prior to their appointment. Decision support documents are entered into the medical record and available to
provider’s prior to the appointment. In order to optimize integration, components were piloted by stakeholders
prior to and during implementation. Primary outcomes are change in appropriate testing for hereditary
thrombophilia and screening for breast cancer, colon cancer, and ovarian cancer one year after study enrollment.
Secondary outcomes include implementation measures related to the benefits and burdens of the family health
system and its impact on clinic workflow, patients’ risk perception, and intention to change health related
behaviors. Outcomes are assessed through chart review, patient surveys at baseline and follow-up, and provider
surveys. Clinical validity of the decision support is calculated by comparing its recommendations to those made by
a genetic counselor reviewing the same pedigree; and clinical utility is demonstrated through reclassification rates
and changes in appropriate screening (the primary outcome).
Discussion: This study integrates a computerized family health history system within the context of a routine well-
visit appointment to overcome many of the existing barriers to collection and use of family history information by
primary care providers. Results of the implementation process, its acceptability to patients and providers,
modifications necessary to optimize the system, and impact on clinical care can serve to guide future
implementation projects for both family history and other tools of personalized medicine, such as health risk
assessments.
* Correspondence: lori.orlando@duke.edu
1Department of Medicine, Duke University, 3475 Erwin Rd, Durham, NC,
27705, USA
Full list of author information is available at the end of the article
Orlando et al. BMC Health Services Research 2011, 11:264
http://www.biomedcentral.com/1472-6963/11/264
© 2011 Orlando et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
In 2002 the CDC launched the Family History Public
Health Initiative, founded upon the principle that family
history is an under used but effective tool for risk strati-
fication. Two of the stated goals are to develop tools to
enhance family health history (FHH) collection and to
evaluate whether family history-based strategies work.
Given that primary care providers are the first (and
sometimes only) provider most patients see and are
long-term partners and coordinators in their care, pri-
mary care practices play a crucial role in collecting and
integrating FHH into an individual’s personalized health
plan. They, therefore, are a natural choice as partners in
studying the implementation of family history collection
into the medical decision making process.
Although FHH is considered a standard component of
the medical interview and several guidelines tie screen-
ing strategies to risk based upon family history, substan-
tial barriers exist to widespread adoption in clinical
practice. Barriers can be broadly categorized into those
related to collecting family history and those related to
acting upon family history. Among those related to col-
lecting family history are: 1) most primary care practices
do not have the resources or the time to collect a com-
plete FHH or to update it [1]; 2) many patients are
either unaware or have limited knowledge about their
FHH and are therefore not able to answer questions
accurately and completely at the point of care [2]; and
3) many providers do not have adequate training and
thus fail to recognize all but the most straightforward
patterns related to inherited syndromes [3,4]. Among
the barriers related to acting upon family history are the
lack of clear cut recommendations about how to man-
age moderate and high risk patients, and the lack of
adequate communication and support from family his-
tory specialists, genetic counselors, and subspecialists
that are necessary to provide appropriate management.
As part of a personalized medicine research program,
The Genomedical Connection, a consortium between
Duke University, the University of North Carolina at
Greensboro, and the Moses Cone Health System in
Greensboro, NC funded by the Department of Defense,
developed a computerized self-administered FHH collec-
tion tool with integrated decision support, MeTree, to
overcome barriers to the integration of FHH into pri-
mary care.
Methods/Design
The Genomedical Connection developed a computerized
self-administered FHH collection and decision support
tool (MeTree) as part of a model for the practice of
genomic medicine in primary care. This study was IRB
approved by all three institutional partners as well as by
the Department of Defense. The goal of the tool is to
assist primary care providers in identifying high risk
individuals who may need additional screening or refer-
rals to maximize their preventative health care. It col-
lects a 3 generation FHH on 48 conditions and
currently provides decision support for 5 test conditions:
breast cancer, ovarian cancer, colon cancer, thrombosis,
and hereditary cancer syndromes. Diseases collected by
the tool are shown in table 1. Decision support is pro-
vided in the form of printed reports. A patient report
outlines important points for patients to discuss with
their providers, while a provider report contains guide-
line recommendations for prevention and screening
based upon estimated disease risk. Both receive a copy
o ft h ep e d i g r e ea n dt h ep r o v i d e ri sg i v e nat a b u l a r
report of the family history as well. Examples reports
are available in Additional File 1, Appendix A (provider
report) and Additional File 2, Appendix B (patient
report).
Integration into clinic workflow
In order to minimize the burden on providers and the
clinical staff, the MeTree tool is designed to have both a
web and computer interface to permit access from the
clinic for patients who do not have internet access at
Table 1 Diseases collected by MeTree
Types of Cancer
Brain Lung Small Bowel
Breast Lymphoma Stomach
Cervical Melanoma Testicular
Colon Pancreatic Thyroid
Kidney Prostate Uterine
Leukemia Ovarian Unknown
Liver Skin (Not Melanoma) Other, Specify
Other Conditions
Alzheimer Disease/
Dementia
Heart Attack Multiple Sclerosis
Anemia High Blood Pressure Osteoporosis
Asthma High Cholesterol Parkinson Disease
Blood Clots in Veins Inflammatory Bowel
Disease
Rheumatoid Arthritis
Colon polyps Lupus Seizures
Diabetes Macular Degeneration Stroke
Glaucoma Multiple Miscarriages Thyroid Disease
Hereditary Cancer Syndromes
Hereditary Breast & Ovarian Cancer
(BRCA1/BRCA2 genes)
LiFraumeni
Syndrome
(TP53 gene)
Hereditary Nonpolyposis Colon Cancer
(MLH1/MSH2/MSH6 genes)
Cowden Syndrome
(PTEN gene)
Familial Adenomatous Polyposis
(APC gene)
Other Cancer
Syndromes
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Page 2 of 7home. An introductory letter is provided to patients
explaining the tool and the type of information they
should collect from family members (along with a work-
sheet to complete) before attempting to use it; however,
if they find that they cannot answer a question they are
allowed to stop work and come back to it at a later date
if necessary. Upon completion, the reports and pedigrees
are printed by clinic staff with appropriate patient docu-
ments given to the patient and provider documents
entered into the medical record to be available at the
time of the appointment.
Hybrid type 2 Effectiveness and Implementation Clinical
Trial
Ultimately, the goal of MeTree is to help providers not
only collect family history but to use it to detect those
at high risk for disease who could benefit from alterna-
tive management strategies. To do this, the tool is
designed to maximize sensitivity (especially around
genetic counseling referrals for identification of heredi-
tary cancer syndromes), understanding that it will be at
the expense of a slightly lowered specificity. In order to
assess the operating characteristics of the tool, to modify
it to achieve the ideal combination of sensitivity and
specificity, to measure its impact on patient and provi-
der behaviors, and to identify factors critical to success-
ful implementation in primary care, a hybrid type 2 trial
of effectiveness and implementation is being conducted
in 3 primary care clinics in the Moses Cone Health Sys-
tem. This type of hybrid study combines primary effec-
tiveness outcomes with implementation outcomes,
which are described in more detail in the outcomes sec-
tion [5]. Two clinics serve as intervention sites and a
third as a concurrent control to account for temporal
trends in study outcomes.
Of the two intervention sites, one clinic has 8 board-
certified internal medicine providers and 1 nurse practi-
tioner while the other has 3 board-certified internal
medicine physicians and 1 board-certified family medi-
cine physician. Between the two sites there are 31,000
unique patient-visits annually and both have electronic
medical records, onsite laboratories, and admitting privi-
leges to Moses Cone Hospital. A computer with access
to MeTree is available in a private room in each clinic.
The control clinic has 6 board-certified family medicine
physicians and 2 physician assistants. It serves ~20,000
patients annually and has an electronic medical record
system.
Recruitment
All adult patients (over age 18) scheduled for an upcom-
ing well visit in the 2 primary care practices are mailed
an invitation to participate in the trial; only adoptees
and non-English speakers are excluded. Those who
meet these criteria and agree to participate (see Figure
1 )a r ei n s t r u c t e db yt h es t u d yc o o r d i n a t o r so nh o wt o
use the tool and how to collect medical history from
family members. They are also mailed the introductory
letter and FHH collection worksheet (described in the
integration into clinical workflow section). Participants
arrive one hour early on the day of their provider
appointment, are consented, and complete MeTree.
Study coordinators are available to answer questions
during the entire process, and upon completion, to print
the appropriate documents for the patient and provider.
Provider documents are scanned into the EMR by the
nurse and the originals are handed to the provider as
they enter the patient’sr o o m .I ti sl e f tu pt ot h ep r o v i -
ders and patients to act, or not, upon the recommenda-
tions as they deem appropriate.
Figure 1 Study flow diagram for patient recruitment and
inclusion.
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have been enrolled. Baseline characteristics of partici-
pants are similar to the general clinic population (table
2). Other measured characteristics include average
family size of 10 +/- 5 (range 1-30) and an education
level of: high school or less (14%), high school degree
(63%), at least some graduate level courses (23%).
Outcomes and measures
The primary effectiveness outcomes are the change in 1)
appropriate testing for hereditary thrombophilia, 2)
appropriate referrals to genetic counseling for risk of
hereditary cancer syndromes, and 3) appropriate screen-
ing rates for breast cancer, colon cancer, and ovarian
cancer one year after using MeTree. The appropriate-
ness of the risk management strategy recommended by
MeTree and the risk management strategy recom-
mended by the provider are determined by a genetic
counselor after reviewing the pedigree. Secondary effec-
tiveness outcomes, implementation outcomes, and cov-
ariates measured are shown in Table 3. Implementation
is assessed using a mixed methods formative evaluation
in order to identify barriers and potential solutions to
those barriers that may potentiate broader adoption of
the FHH system among primary care clinical settings.
Examples of how formative evaluation results will be
used include development of FAQs, modification of the
tool interface and/or content, and development of
resources to facilitate workflow changes.
In the control clinic, rates of breast, colon, and ovar-
ian cancer screening, thrombophilia testing, and genetic
counselor referrals are assessed via chart review of 50
patients for each of the 7 providers, during two time
periods: the year prior to the study start date and the
year after study start date. Consecutive patients seen
during the time period under evaluation are considered
if they meet study entry criteria. Changes in the rates of
screening between the two periods will serve as a guide
for local temporal trends in screening rates and genetic
counseling referrals and will be used to assist in the
interpretation of changes seen in the intervention
clinics.
Analyses
The primary goals of this project are to measure the
impact in the primary care setting of a structured FHH
assessment tool on evidence-based prevention and
screening for breast cancer, ovarian cancer, colon cancer,
and thrombosis, and identification of hereditary cancer
syndromes, as well as to measure the impact of imple-
mentation on patients, providers, and clinic processes.
For the effectiveness outcomes, we will calculate the
proportion of subjects at the implementation clinics
appropriately referred for genetic services (either to a
genetic counselor or for a genetic test), or screening stu-
dies for breast, colon, and/or ovarian cancer. Although
the study is implemented at the level of the clinical
practice, the likelihood of clustering is low given that all
participants undergo the intervention, the two clinical
sites are similar in nature and serve similar patient
populations within the same community, and the inter-
vention is aimed at both the patient and the provider.
To fully address the possibility that clustering may
occur, we will calculate its design effect [6]; if the design
effect is 1, we will use standard tests and generalized
linear mixed models with clinic and provider as random
effects, if not we will adjust the confidence intervals
using a conditional logistic regression [7]. Effect size
bias is extremely unlikely in this non-randomized study
as all individuals receive the intervention, preventing the
imbalance in treatment assignment that can lead to
inaccurate point estimates [7].
Sample size and Power
The empirical power for the comparison of referral rates
between the implementation clinics and the control
clinic will be a function of the rate in the control clinic
at one year. For the purposes of power calculations we
estimated the baseline referral proportion of 1% for
genetic counseling, 77% for breast cancer screening, 59%
for colon cancer screening based on a random sample
of patient charts prior to launch of the MeTree tool in
the implementation clinics and the CDC’s Behavioral
Risk Factor Surveillance System Survey data for North
Carolina [8]. Based on this baseline percentage, using an
alpha value of 0.025 to adjust for the comparisons with
two clinics, a sample of 500 individuals will result in
Table 2 Baseline characteristics of participants enrolled
to date as compared to the general clinic population
Study
Participants
Baseline Clinic
Population
Gender
Male 192 (41.2%) 56.1%
Female 276 (58.8%) 42.7%
Ethnicity
White 386 (82.4%) 61.7%
Black 66 (14.1%) 12.5%
Hispanic 10 (2.1%) 1.6%
Asian 1 (0.2%) 0.4%
Am. Indian/
Eskimo
2 (0.4%) 0.4%
Ashkenazi Jewish 1 (0.2%) 0
Unknown 0 18.5%
Other 3 (0.6%) 1.6%
Age mean (sd) 58.2 (12.6) 59.3 (13.5)
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Variable Measure Source
Primary Effectiveness Outcomes
Appropriate breast cancer screening Risk-based guideline screening performed Genetic counselor pedigree and chart review
Appropriate ovarian cancer screening Risk-based guideline screening performed Genetic counselor pedigree and chart review
Appropriate colon cancer screening Risk-based guideline screening performed Genetic counselor pedigree and chart review
Appropriate hereditary thrombophilia
testing
Risk-based guideline screening performed Genetic counselor pedigree and chart review
Secondary Effectiveness Outcomes
Patient health-related behaviors Diet
Exercise
Smoking status
Intention to obtain cancer screening
Knowledge about genetic testing
HINTS[16] given at baseline, 3 month and 12
months
Provider care patterns Orders for:
Screening studies
Referrals to GC
Genetic testing
Documentation of:
Disease risk
MeTree recommendations
Chart review
MeTree operating characteristics Sensitivity and specificity
Net Reclassification
Number needed to treat to identify high
risk
Subgroups affected by reclassification
Pedigree review by GC
Pedigree review by PCP
Costs Referrals, office visits, procedures, testing Chart review
Implementation Outcomes
Patient experience Satisfaction
Preparedness
Ease of use
Level of anxiety
Time to use
Questions\resource needs
Post-MeTree survey
MeTree
Study Coordinator
Provider experience Agreement with recommendations
Does it change practice
Recommend it to peers
Quality and usefulness of reports
Impact on patient flow
Time spent discussing MeTree reports
Provider survey and interviews
Clinic needs Resource needs to implement
Assistance required for patients/providers
Training/time required for clinic staff
Study coordinators
Interviews
Covariates
Demographics Age
Gender
Ethnicity
MeTree input
Education level Baseline survey
Insurance Baseline survey
Family Size
% with cancer
MeTree input
BMI Measured at triage
Clinic
Provider Year of medical school graduation
Gender
Provider survey
GC = genetic counselor; PCP = primary care provider
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implementation clinic of 0.147 or higher and a sample
of 1000 individuals will result in power of 80% or higher
for a screening proportion of 0.132 in the larger clinic.
Alternatively if we don’t consider the baseline propor-
tion fixed but estimate it from the control clinic, we will
be able to detect a difference in the proportions of 0.09
for the smaller clinic and 0.06 for the larger clinic with
80% power at an alpha of 0.025. Thus even analyzing
each of the clinics separately we will have sufficient
power to test the hypothesis that the MeTree tool
implementation increased genetic referral rates.
Discussion
The simplest and least expensive form of genetic assess-
ment, family history, is widely overlooked in medical
practice. It has long been taught as one of the core
foundations of the medical interview, yet over the years
these skills have been lost or overwhelmed by the pres-
sures and time constraints of day to day practice. Bring-
ing family history back into the realm of medical
decision making is important for multiple reasons. First,
disease prevention has the potential to reduce the ever
escalating costs of medical care. However, disease pre-
vention relies entirely upon accurate disease risk predic-
tion. Family history has been shown to improve disease
risk prediction for colon cancer [9], breast cancer [10],
and cardiovascular disease [11], among others. Second,
using family history to predict disease requires several
skills: understanding what family history is saying about
risk, understanding how to communicate risk to
patients, and using risk information to motivate beha-
vior change. By developing an electronic family history
collection and decision support tool to assist providers,
we anticipate that providers will be able to reincorporate
family history based decision making into their medical
practice. In addition, continued use may permit provi-
ders to establish and hone their skills in a way that they
can start to apply them to other risk-based fields, thus it
may serve as an educational stepping stone to newer
and more complicated areas of genetics and genomics.
Despite these benefits of family history taking little is
known about its clinical validity or utility [12]. Our
study fills this significant gap by directly addressing the
question of both validity and utility. Although the one
year follow up will not permit the use of hard outcomes
such as the incidence of breast, colon, or ovarian cancer,
screening is indicated by the United States Preventive
Task Force and the American Cancer Society because of
evidence that screening reduces morbidity and mortality;
but is considerably underutilized [13,14]. With this in
mind screening patterns may be used as an acceptable
intermediate endpoint.
Another important gap our study addresses is imple-
mentation. Multiple barriers to implementation exist. At
the patient level inaccurate or limited information about
family history is widespread [12]. At the provider level,
as mentioned above, time constraints and lack of train-
ing are becoming more and more difficult to
address [15]. Developing an electronic tool for collecting
family history and providing decision support at the
point of care are essential keys to addressing these bar-
riers and our tool, MeTree does just that; however inte-
grating it into practice creates its own set of barriers.
Technology can be a barrier for both patients and provi-
ders, as can the resources required to integrate it. We
monitor all stakeholders and measure every aspect of
the implementation process in order to get a clear pic-
ture of what barriers have been solved with MeTree and
what new ones arise in their place. At the end of this
study we expect to have an excellent idea of not only
whether such a tool has value in clinical practice but
also how best to facilitate widespread adoption. Ulti-
mately, it may serve as a demonstration project to guide
integration of other personalized medicine tools, such as
health risk assessments, into clinical practice.
Additional material
Additional file 1: Example of a Provider Report. Shows the type of
information a provider report contains and its layout.
Additional file 2: Example of a Patient Report. Shows the type of
information a patient report contains and its layout.
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